<DOC>
	<DOCNO>NCT03096730</DOCNO>
	<brief_summary>To explore compare antihyperalgesic effect Dexmedetomidine , Nalmefene , combination receive anesthesia induction . To evaluate examine incidence adverse effect purpose select optimum dose .</brief_summary>
	<brief_title>Effect Dexmedetomidine Combined With Low-dose Nalmefene Preventing Remifentanil-induced Postoperative Hyperalgesia</brief_title>
	<detailed_description>There dramatically increase number evidence administration potent , ultra-short-acting opioid remifentanil seem cause opioid-induced hyperalgesia ( OIH ) frequently predictably compare others , likely due rapid onset offset . Therefore , prophylaxis remifentanil induce hyperalgesia indispensable postoperative comfort satisfaction . There deny fact OIH related central glutaminergic system N-methyl-d-aspartate ( NMDA ) receptor-activation induced central sensitization . Dexmedetomidine 2-adrenergic agonist show synergize opioids . Dexmedetomidine inhibit NMDAR excitability reduce phosphorylation N-methyl-D-aspartate receptor 2B subunit phosphorylation spinal dorsal horn induce remifentanil , thereby achieve goal reduce OIH . Nalmefene pure opioid receptor antagonist antagonize Mu receptor , alleviate central sensitization NMDA , thereby reduce OIH . At time report literature , opioid receptor bimodeï¼šOn one hand mediate Gs protein-mediated pain , respiratory depression , nausea vomiting , etc ; hand couple Gi / Go protein mediate analgesic effect . Low-dose nalmefene ( &lt; 1.0ug / kg ) opioid receptor antagonist antagonize role Gs protein-coupled opioid receptor , block pathway opioid excitatory effect , thereby reduce incidence adverse reactions.The follow study carry evaluate whether dexmedetomidine combine nalmefene safely effectively apply prevent postoperative hyperalgesia induce remifentanil patient undergo Laparoscopic gynecological surgery .</detailed_description>
	<mesh_term>Hyperalgesia</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Sufentanil</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Nalmefene</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Patients schedule undergo Gynecological surgery short general anesthesia 13 hour . 2 . American Society Anesthesiologists physical status III . 3 . Written inform consent obtain subject . 1 . Subject diagnosis Coronary heart disease , bronchial asthma , cardiac , lung , hepatic renal insufficiency . 2 . Subject diagnosis Severe high blood pressure , diabetes , obesity ( BMI &gt; 30 ) . 3 . Subject history chronic pain , history alcohol opioid abuse , preexist therapy opioids , intake analgesic drug within 48 h surgery . 4 . .Subject Pregnancy , psychiatric disease . 5 . Subject contraindication use patientcontrolled analgesia ( PCA ) . 6 . Inability understand Study Information Sheet provide write consent take part study .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Remifentanil</keyword>
	<keyword>Opioid-induced hyperalgesia</keyword>
	<keyword>Postoperative pain</keyword>
	<keyword>pain intensity</keyword>
</DOC>